Cost Of Revenue - InterCure Ltd (NASDAQ:INCR) - Alpha Spread
I

InterCure Ltd
NASDAQ:INCR

Watchlist Manager
InterCure Ltd
NASDAQ:INCR
Watchlist
Price: 1.86 USD Market Closed
Market Cap: 84.8m USD
Have any thoughts about
InterCure Ltd?
Write Note

InterCure Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

InterCure Ltd
Cost of Revenue Peer Comparison

Comparables:
TEVA
RDHL
SLGL
MDWD
R
REKA

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
I
InterCure Ltd
NASDAQ:INCR
Cost of Revenue
-â‚Ş247.2m
CAGR 3-Years
-93%
CAGR 5-Years
N/A
CAGR 10-Years
-63%
Teva Pharmaceutical Industries Ltd
NYSE:TEVA
Cost of Revenue
-$8B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
2%
Redhill Biopharma Ltd
NASDAQ:RDHL
Cost of Revenue
-$4.9m
CAGR 3-Years
51%
CAGR 5-Years
-19%
CAGR 10-Years
-17%
Sol Gel Technologies Ltd
NASDAQ:SLGL
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mediwound Ltd
NASDAQ:MDWD
Cost of Revenue
-$17.5m
CAGR 3-Years
-4%
CAGR 5-Years
-31%
CAGR 10-Years
-35%
R
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Cost of Revenue
-â‚Ş249.5m
CAGR 3-Years
-8%
CAGR 5-Years
-13%
CAGR 10-Years
-4%

See Also

What is InterCure Ltd's Cost of Revenue?
Cost of Revenue
-247.2m ILS

Based on the financial report for Dec 31, 2023, InterCure Ltd's Cost of Revenue amounts to -247.2m ILS.

What is InterCure Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-63%

Over the last year, the Cost of Revenue growth was -8%. The average annual Cost of Revenue growth rates for InterCure Ltd have been -93% over the past three years , and -63% over the past ten years .

Back to Top